-
1.发明授权Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors 失效使用蛋白酪氨酸磷酸酶ζ作为生物分子靶向治疗和可视化脑肿瘤公开(公告)号：US06455026B1
公开(公告)日：2002-09-24
申请号：US09816703
申请日：2001-03-23
申请人： Sabine Mueller , Thorsten Melcher , Daniel J. Chin
发明人： Sabine Mueller , Thorsten Melcher , Daniel J. Chin
IPC分类号： A61K5100
CPC分类号： A61K51/1093 , A61K47/6871 , A61K51/1075
摘要： The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents that specifically bind to human protein tyrosine phosphatase-zeta (PTP&zgr;) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为脑肿瘤治疗疗法的生物分子靶标的用途。 具体地，本发明涉及特异性结合人蛋白质酪氨酸磷酸酶ζ（PTP＆zgr）用于治疗和观察患者脑肿瘤的免疫治疗和免疫成像剂的用途。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。
-
公开(公告)号：US07060275B2
公开(公告)日：2006-06-13
申请号：US10652981
申请日：2003-08-28
申请人： Sabine Mueller , Thorsten Melcher , Daniel Chin
发明人： Sabine Mueller , Thorsten Melcher , Daniel Chin
IPC分类号： A61K39/395 , A61K39/40 , C07H21/02
CPC分类号： A61K49/0002
摘要： The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTPζ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
-
3.发明申请Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta 审中-公开针对受体蛋白酪氨酸磷酸酶ζ的单克隆抗体公开(公告)号：US20050260132A1
公开(公告)日：2005-11-24
申请号：US11097728
申请日：2005-03-31
申请人： Daniel Chin , Erik Foehr , Sabine Mueller , Thorsten Melcher
发明人： Daniel Chin , Erik Foehr , Sabine Mueller , Thorsten Melcher
IPC分类号： A61K39/395 , A61K47/48 , A61K51/00 , C07K16/28 , C07K16/30
CPC分类号： C07K16/3023 , A61K47/6819 , A61K47/6849 , A61K47/6855 , A61K47/6857 , A61K47/6861 , A61K47/6865 , A61K2039/505 , C07K16/28 , C07K16/3015 , C07K16/3038 , C07K16/3053 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to a method of inhibiting growth of tumor cells which overexpress a receptor protein tyrosine phosphatase zeta (PTPζ) by treatment of the cells with antibodies which recognize PTPζ and/or inhibit PTPζ function. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
摘要翻译： 本发明涉及通过用识别PTPzeta和/或抑制PTPzeta功能的抗体处理细胞来抑制过表达受体蛋白酪氨酸磷酸酶ζ（PTPzeta）的肿瘤细胞生长的方法。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。 本发明还提供蛋白质PTPzeta，PTPzeta SM1和PTPzeta SM2的新型剪接变体。 还提供了针对编码这些变体的剪接mRNA特异性的核酸探针和对新蛋白特异的亲和试剂。
-
4.发明申请Use of protein biomolecular targets in the treatment and visualization of brain tumors 失效蛋白质生物分子靶标在脑肿瘤的治疗和可视化中的应用公开(公告)号：US20050074400A1
公开(公告)日：2005-04-07
申请号：US10652981
申请日：2003-08-28
申请人： Sabine Mueller , Thorsten Melcher , Daniel Chin
发明人： Sabine Mueller , Thorsten Melcher , Daniel Chin
IPC分类号： A61K49/00 , A61K51/00 , A61K39/395
CPC分类号： A61K49/0002
摘要： The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTPζ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为脑肿瘤治疗疗法的生物分子靶标的用途。 具体地，本发明涉及特异性结合一种或多种人蛋白质的血管生成素相关蛋白2（ARP-2）分泌的蛋白质，富含半胱氨酸（SPARC）c-met原核蛋白的免疫治疗和免疫成像剂的用途。 癌基因（C-MET，）brevican（BEHAB）CD-44抗原（CD-44）四质蛋白3（TSPN3）多效素（PTN）骨桥蛋白（OPN）血管活性肠肽受体-2（VIPR-2） 和受体蛋白酪氨酸磷酸酶ζ（PTPzeta），用于治疗和观察患者脑肿瘤。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。 本发明还提供蛋白质PTPzeta，PTPzeta SM1和PTPzeta SM2的新型剪接变体。 还提供了针对编码这些变体的剪接mRNA特异性的核酸探针和对新蛋白特异的亲和试剂。
-
5.发明授权公开(公告)号：US07368098B2
公开(公告)日：2008-05-06
申请号：US10328544
申请日：2002-12-23
IPC分类号： G01N33/574
CPC分类号： A61K49/0004 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/574
摘要： The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging agents that specifically bind to an identified brain tumor target protein are provided. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为肿瘤治疗疗法的生物分子靶标的用途。 该蛋白质也在来自腺癌，非黑素瘤和肾癌细胞的组织中表达。 提供特异性结合鉴定的脑肿瘤靶蛋白的免疫治疗和免疫成像剂。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。
-
6.发明授权Use of biomolecular targets in the treatment and visualization of brain tumors 有权在脑肿瘤的治疗和可视化中使用生物分子靶标公开(公告)号：US07014838B2
公开(公告)日：2006-03-21
申请号：US10329258
申请日：2002-12-23
CPC分类号： A61K49/0004 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/574
摘要： The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents, which specifically bind to one or more of the identified brain tumor protein targets. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为脑肿瘤治疗疗法的生物分子靶标的用途。 具体地，本发明涉及特异性结合一种或多种所鉴定的脑肿瘤蛋白靶标的免疫治疗和免疫成像剂的用途。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。 还提供了针对编码这些变体的剪接mRNA特异性的核酸探针和对新蛋白特异的亲和试剂。
-
7.发明申请公开(公告)号：US20080226646A1
公开(公告)日：2008-09-18
申请号：US12045448
申请日：2008-03-10
IPC分类号： A61K39/395 , C07K16/18 , A61K31/70 , C12N5/06 , A61P43/00
CPC分类号： A61K49/0004 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/574
摘要： The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging agents that specifically bind to an identified brain tumor target protein are provided. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为肿瘤治疗疗法的生物分子靶标的用途。 该蛋白质也在来自腺癌，非黑素瘤和肾癌细胞的组织中表达。 提供特异性结合鉴定的脑肿瘤靶蛋白的免疫治疗和免疫成像剂。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。
-
8.发明申请USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS 有权生物分子靶向在脑肿瘤治疗和可视化中的应用公开(公告)号：US20060024233A1
公开(公告)日：2006-02-02
申请号：US10329258
申请日：2002-12-23
CPC分类号： A61K49/0004 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/574
摘要： The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents, which specifically bind to one or more of the identified brain tumor protein targets. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.
摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为脑肿瘤治疗疗法的生物分子靶标的用途。 具体地，本发明涉及特异性结合一种或多种所鉴定的脑肿瘤蛋白靶标的免疫治疗和免疫成像剂的用途。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。 还提供了针对编码这些变体的剪接mRNA特异性的核酸探针和对新蛋白特异的亲和试剂。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.027 秒)
